Hemedex, Inc. was founded in 2000 to commercialize a proprietary platform technology conceived at the Massachusetts Institute of Technology (M.I.T.), for the purpose of measuring tissue perfusion (i.e., blood flow at the capillary level). This technology addresses high clinical need situations in complex medical and surgical procedures. These complex procedures often involve compromised vasculature and other serious pathophysiology, which results in high rates of morbidity, delayed recuperation, poor patient outcome and higher overall costs. The Company's patented technology provides clinicians with a powerful tool to generate valuable prognostic data, which can provide an early warning of impending tissue ischemia and help target appropriate therapies rapidly and accurately.

Hemedex's first product, the Bowman Perfusion Monitor™, which has been used successfully in neurosurgery, reconstructive surgery and organ transplantation clinical studies, provides a minimally invasive technique to accurately and continuously measure perfusion in small volumes of tissue. Prior to the Bowman system, the ability to get continuous, real time perfusion measurements in absolute units (ml/100g-min) did not exist. These measurements are a long sought after and important parameter in understanding and managing critical medical situations. Data from the Bowman Perfusion Monitor will help guide physicians in developing and implementing effective treatments quickly, creating the potential to improve patient outcomes and lower costs.

The Company's proprietary technology in the clinical application of thermal diffusion can be formulated to develop multiple products addressing unmet needs in many clinical areas such as neurosurgical monitoring, organ transplantation, cardiovascular monitoring, reconstructive surgery, critical care and endothelial function, among others.

[ TOP ]